Gilead's experimental HIV treatment shows low discontinuation rates in studies

Core Viewpoint - Gilead Sciences' experimental single-tablet HIV treatment demonstrates low discontinuation rates and high patient satisfaction, indicating its potential as a viable option for patients after viral suppression [1] Group 1: Treatment Efficacy - The experimental treatment showed discontinuation rates due to adverse events of 1.6% and 0.5% in the two treatment arms, which are considered low [1] - After 48 weeks, 0.8% of patients on the combination pill had detectable virus levels, compared to 1.1% of those on multi-tablet regimens, suggesting better viral suppression [1] Group 2: Patient Satisfaction - Participants reported higher treatment satisfaction after switching to the experimental single-tablet regimen, as noted in a paper published in The Lancet [1] Group 3: Regulatory Plans - Gilead plans to submit data from the trials to regulatory authorities, although the combination treatment has not yet received approval [1]